Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of C1K in Healthy Subjects
NCT05701644Phase 1Completed
- Sponsor
- Ensol Biosciences Inc.
- Start
- Jan 2023
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of C1K in triple-negative breast cancer (TNBC) (5 arms), sponsored by Ensol Biosciences Inc. Primary endpoints: Safety and Tolerability Assessment, Maximum concentration of C1K in plasma at Day 15 and 6 more. Started Jan 2023; status: completed.
02
Drugs
C1K
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05701644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05701644.